scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: scpharmaceuticals.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | $20.00 | Buy | Craig Hallum |
| 12/1/2022 | $25.00 | Outperform | Cowen |
| 10/21/2022 | $14.00 | Buy | Jefferies |
| 10/11/2022 | $11.00 | Mkt Perform → Outperform | SVB Leerink |
| 8/2/2022 | $10.00 | Buy | Maxim Group |
| 9/9/2021 | $6.00 | Market Perform | SVB Leerink |
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologist's perspective on the use of FUROSCIX for treating fluid overload in heart failure and potential use for patients with chronic kidney disease (CKD) on Tuesday, October 22, 2024 at 1:00 PM ET. To register, click here. https://lifescievents.com/event/scpharmaceuticals/ The event will feature Dr. Michael Aaronson, MD (Lincoln Nephrolog
BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also be meeting with investors that day. A webcast of the presentation can be accessed here or under "News & Events" in the Investor Relations section of the Company's website, www.scPharmaceuticals.
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient car
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discou
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced non-dilutive financings totaling up to $125 million with
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Food and Drug Administration (FDA) has approved its Supplemental New Drug
SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced positiv
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares ("Shares") of its common stock or, in lieu of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase Shares (the "Offering"). scPharmaceuticals also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Shares offered in the Offering. All Shares and Pre-Funded Warrants to be sol
BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024, to discuss the financial results for the second quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259. To access the new Call me™ feature, which avoids hav
BURLINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. In Ty
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form
4/A - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13D/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G - scPharmaceuticals Inc. (0001604950) (Subject)
SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient car
BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024, to discuss the financial results for the second quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259. To access the new Call me™ feature, which avoids hav
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14, at 4:30pm ET BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results for the first quarter 2024 and provide a business update. Participants should dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with the conference code 89054. To access the Call Me™ feature, which avoids having to wait for an operator, click h
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January Ended 2023 with cash, cash equivalents and short-term investments of $76 million Company to host investor conference call and webcast today, Wednesday, March 13, at 4:30pm ET BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of inf
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial results for the fourth quarter and full-year 2023 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13744172. To access the new Call me™ feature, which avoids having to wai
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. Business Update For the third quarter ended September 30,
BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss the financial results for the third quarter 2023 and provide a business update. Participants should dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) with the conference code 10022564. To access the new Call me™ feature, which avoids having to wait for an opera
Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today, Thursday, August 10, at 4:30pm ET BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. Business Update For the second quarter ended June 30, 2023, scPh
BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 10, 2023, to discuss the financial results for the second quarter 2023 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13739659. To access the new Call me™ feature, which avoids having to wait for an op
10-Q - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
424B5 - scPharmaceuticals Inc. (0001604950) (Filer)
424B5 - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
10-Q - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00
Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00
Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00
SVB Leerink upgraded scPharmaceuticals from Mkt Perform to Outperform and set a new price target of $11.00
Maxim Group initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $10.00
SVB Leerink initiated coverage of scPharmaceuticals with a rating of Market Perform and set a new price target of $6.00
scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. In Type D meeting feedback provided by the FDA last year, the ag
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price target.
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.44) by 18.18 percent. The company reported quarterly sales of $6.10 million which beat the analyst consensus estimate of $5.98 million by 2.05 percent. This is a 195.69 percent increase over sales of $2.06 million the same period last year.
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 25.93% to $8.06. The company's market cap stands at $236.5 million. Etao International Co (NASDAQ:ETAO) shares moved upwards by 25.61% to $3.58. The market value of their outstanding shares is at $18.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares rose 11.11% to $2.5. The company's market cap stands at $21.3 million. scPharmaceuticals (NASDAQ:SCPH) stock moved upwards by 10.7% to $5.69. The company's market cap stands at $205.1 million. Molecular
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price target.
scPharmaceuticals (NASDAQ:SCPH) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Earnings scPharmaceuticals beat estimated earnings by 17.0%, reporting an EPS of $-0.35 versus an estimate of $-0.42. Revenue was up $6.10 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.05 which was followed by a 9.0% drop in the share price the next day. To track all earnings releases for scPharmaceuticals visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $6.096 million which beat the analyst consensus estimate of $5.525 million by 10.33 percent.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expected to report earnings for its fourth quarter. • Optical Cable (NASDAQ:OCC) is likely to report earnings for its first quarter. • Perma-Fix Envirn Servs (NASDAQ:PESI) is likely to report quarterly earnings at $0.06 per share on revenue of $22.50 million. • Dollar Tree (NASDAQ:DLTR) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion. • Magic Software (NASDAQ:MGIC) is expected to report quarterly earnings at $0.19 per share on revenue of $117.50 million.
scPharmaceuticals (NASDAQ:SCPH) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement. Analysts estimate that scPharmaceuticals will report an earnings per share (EPS) of $-0.42. scPharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company missed EPS by $0.05, which was followed by a 8.74% dr